Viking Therapeutics Inc. logo

Viking Therapeutics Inc. (VKTX)

Market Closed
17 Jul, 20:00
NASDAQ (CM) NASDAQ (CM)
$
37. 08
+0.71
+1.9522%
$
4.51B Market Cap
- P/E Ratio
- Div Yield
1.92M Volume
-0.92 Eps
$ 36.37
Previous Close
Add Transaction
Day Range
35.29 37.63
Year Range
22.96 43.15
Want to track VKTX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note

Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $37.08, representing a +1.95% change from its previous close.

Zacks | 1 day ago
Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?

Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?

VKTX's Q2 report could hinge on VK2735 pipeline updates as investors await progress on obesity studies and maintenance dosing plans.

Zacks | 1 day ago
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know

Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know

Viking Therapeutics, Inc. (VKTX) reached $38.86 at the closing of the latest trading day, reflecting a -5.54% change compared to its last close.

Zacks | 1 week ago
Viking Therapeutics: Still Cheap, But Watch Double Top

Viking Therapeutics: Still Cheap, But Watch Double Top

Viking Therapeutics is advancing its GLP-1 weight-loss pipeline, with Phase 3 trials progressing and oral formulation development accelerating. The consensus analyst price targets average $92.58, suggesting substantial upside. Recent biotech sector M&A highlights VKTX's potential valuation in a rapidly expanding GLP-1 market.

Seekingalpha | 1 week ago
Buyout Buzz Around VKTX Is Back: What's Fueling the Speculation?

Buyout Buzz Around VKTX Is Back: What's Fueling the Speculation?

Viking Therapeutics' expanding obesity pipeline and upcoming VK2735 data reignite buyout speculation as investors weigh its growing strategic appeal.

Zacks | 1 week ago
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today

Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $39.97, moving 5.13% from the previous trading session.

Zacks | 1 week ago
How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?

How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?

Viking Therapeutics could have a medicine on the market within two years. To capture market share, the new offering will need to fight a pair of pharma juggernauts.

Fool | 2 weeks ago
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $37.48, denoting a -3.92% move from the preceding trading day.

Zacks | 2 weeks ago
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?

Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Zacks | 2 weeks ago
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $36.97, denoting a -2.38% move from the preceding trading day.

Zacks | 3 weeks ago
VKTX Stock Jumps on Phase I Study Initiation for New Obesity Drug

VKTX Stock Jumps on Phase I Study Initiation for New Obesity Drug

Viking Therapeutics jumps after it starts its first human study of VK3019, expanding its obesity pipeline with a second candidate alongside its lead program, VK2735.

Zacks | 3 weeks ago
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know

Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know

In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $30.29, indicating a +2.16% shift from the previous trading day.

Zacks | 1 month ago
Loading...
Load More